Get started
Author

Sedat Biter

Observed names: Biter, Sedat, S Biter, S. Biter, Sedat BİTER
ORCID: 0000-0002-1053-0668
Observed ORCID: 0000-0002-1053-0668
OpenAlex ID: A5093003933
Regorafenib Treatment for Recurrent Glioblastoma Beyond Bevacizumab-Based Therapy: A Large, Multicenter, Real-Life Study
2024 · Salih Tünbekici, Haydar cagatay Yuksel, et al. · Cancers · 13
PDF
The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study
2024 · Hasan Çağrı Yıldırım, Yasin Kutlu, et al. · International Journal of Clinical Oncology · 10
Prognostic and predictive value of systemic inflammatory markers in patients with metastatic gastric and GEJ adenocarcinoma with PD-L1 CPS score ≥ 5: Turkish Oncology Group (TOG) study
2025 · Maral Martin Mildanoglu, Yasin Kutlu, et al. · Scientific Reports · 9
PDF
Can the Pathological Response in Patients with Locally Advanced Gastric Cancer Receiving Neoadjuvant Treatment Be Predicted by the CEA/Albumin and CRP/Albumin Ratios?
2024 · Ertugrul Bayram, Mehmet Mutlu Kidi, et al. · Journal of Clinical Medicine · 7
Real-World Efficacy and Safety of First-Line Nivolumab Plus Chemotherapy in Patients with Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: A Nationwide Observational Turkish Oncology Group (TOG) Study
2024 · Yasin Kutlu, Shute Ailia Dae, et al. · Cancers · 6
Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: a retrospective multi-center study by the Turkish Oncology Group (TOG)
2024 · Arif Akyildiz, Deniz Can Guven, et al. · European Archives of Oto-Rhino-Laryngology · 6
Prognostic Significance of the Combined Albumin-To-Alkaline Phosphatase Ratio (AAPR) and Haemoglobin–Albumin–Lymphocyte–Platelet (HALP) Score in Patients with Metastatic Renal Cell Carcinoma Treated by Targeted Therapy: A New Prognostic Combined Risk Scoring
2025 · Tolga Köşeci, Mustafa Seyyar, et al. · Journal of Clinical Medicine · 5
Immune-related adverse events as predictors of pathological complete response in early-stage triple-negative breast cancer treated with pembrolizumab
2026 · Ali Kaan Güren, Nazım Can Demircan, et al. · Immunotherapy · 4
Health-related quality of life and psychosocial outcomes in long-term survivors treated with immune checkpoint inhibitors: a nationwide multicenter study
2025 · Taha Koray Sahin, Fatih Atalah, et al. · Frontiers in Immunology · 4
PDF
Impact of renin–angiotensin system inhibitors on the clinical outcomes of nivolumab therapy in metastatic non–small cell lung cancer
2026 · Emel Mutlu Ozkan, Ibrahim Karadağ, et al. · Expert Review of Anticancer Therapy · 3
Evaluation of the Meet-URO Score in a Real-World Cohort of mRCC Patients Treated with First-Line TKIs
2025 · Faruk Recep Özalp, Ece Şahin Hafızoğlu, et al. · Journal of Clinical Medicine · 3
PDF
Bevacizumab versus aflibercept with FOLFIRI after FOLFOX and bevacizumab in RAS mutant metastatic colon cancer a Turkish oncology group study
2024 · Serhat Sekmek, Sema Nur Ozsan Çelebi, et al. · Scientific Reports · 3
Baseline vitamin D status and clinical outcomes in advanced non-small cell lung cancer patients treated with nivolumab
2026 · Gözde Ağdaş, Duygu Bayir, et al. · Scientific Reports · 2
PDF
Outcomes of First-Line PARP Inhibitor Therapy in Ovarian Cancer: A Multicenter Retrospective Analysis
2026 · Baris Koksal, Hasan Cagri Yildirim, et al. · Journal of Clinical Medicine · 2
PDF
Real-world comparison of doxorubicin–ifosfamide versus gemcitabine–docetaxel regimens in metastatic uterine leiomyosarcoma: a multicenter retrospective study
2025 · Salih Tunbekici, Gokhan Sahin, et al. · Discover Oncology · 2
PDF
Neoadjuvant Regimens and Their Impact on Adjuvant T-DM1 Outcomes in HER2-Positive Early Breast Cancer
2025 · Ahmet Burak Agaoglu, Atike Pinar Erdogan, et al. · Medicina · 2
PDF
First-Line Treatment After Perioperative FLOT in Recurrent Gastric and Gastroesophageal Junction Cancer: A Turkish Oncology Group (TOG) Multicenter Real-World Analysis
2026 · Mustafa Seyyar, Pervin Can Şancı, et al. · Medicina · 1
Comparison of flat-dose versus weight-based dose nivolumab treatment in NSCLC patients
2026 · Muhammet Cengiz, Oktay Bozkurt, et al. · Scientific Reports · 1
PDF
Real-world outcomes of trastuzumab deruxtecan in patients with HER2+ metastatic breast cancer: Turkish oncology group multicenter study
2026 · Taha Koray Sahin, Fatih Kemik, et al. · Therapeutic Advances in Medical Oncology · 1
Baseline glucose-to-lymphocyte ratio predicts nivolumab outcomes in advanced non-small cell lung cancer: a multicenter retrospective study
2026 · Mustafa Ersoy, Umut Kefeli, et al. · Frontiers in Immunology · 1
PDF
Real-World Treatment Patterns and Survival in Uveal Melanoma: A Multicenter Cohort Study by the Turkish Oncology Group (TOG)
2026 · Sercan On, Selin Cebeci, et al. · Cancers · 1
PDF
Durvalumab-Based First-Line Chemoimmunotherapy in Advanced Biliary Tract Cancer: Real-World Outcomes and Prognostic Factors—A Turkish Oncology Group Study
2025 · Safa Can Efil, Fatih Kus, et al. · Cancers · 1
PDF
Efficacy and safety of doxorubicin–ifosfamide versus gemcitabine–docetaxel as first‐line therapy in advanced nonuterine leiomyosarcoma: A multicenter real‐world study
2025 · Salih Tunbekici, Gokhan Sahin, et al. · International Journal of Cancer · 1
Clinicopathological features and treatment outcomes of patients with fibrolamellar hepatocellular carcinoma: a retrospective multicenter study
2025 · Ali Kaan Güren, Hilal Polat, et al. · Annals of Saudi Medicine · 1
Real-world data on the efficacy and safety of trastuzumab emtansine in patients with metastatic breast cancer previously treated with pertuzumab: Turkish oncology group multicenter study
2024 · Özgecan Dülgar, Sema Türker, et al. · Journal of Chemotherapy · 1
Works count: 59
Citation count: 90
H-index: 6
I10-index: 2
Year
Topic
Type